Although the pattern of genomic variations in MPN–SC patients is not disparate from that of control cases, there is preferential involvement of variants in the inflammatory pathways in these patients, a finding supported by the increased plasma levels of two inflammatory cytokines TGF-β and IL-23. The gene discussed is TGFB1; the disease is myeloproliferative neoplasm.